SNDX
USDSyndax Pharmaceuticals Inc. Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$13.600
Máximo
$15.799
Mínimo
$13.150
Volume
3.36M
Fundamentos da empresa
Capitalização de mercado
1.3B
Setor
Biotecnologia
País
United States
Estatísticas de negociação
Volume médio
2.67M
Bolsa de valores
NMS
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
UBS Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $38
UBS analyst David Dai maintains Syndax Pharmaceuticals with a Buy and raises the price target from $35 to $38.
Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $22
Barclays analyst Peter Lawson maintains Syndax Pharmaceuticals with a Overweight and raises the price target from $19 to $22.
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax's leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an
Syndax Announces Participation in November Investor Conferences
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals with a Buy and maintains $40 price target.
Ações relacionadas
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.